The Use of the Esclera Scleral Contact Lens in the Treatment of Moderate to Severe Dry Eye Disease

The Use of the Esclera Scleral Contact Lens in the Treatment of Moderate to Severe Dry Eye Disease

Author Weber, Sarah La Porta Autor UNIFESP Google Scholar
de Souza, Rodrigo Becco Autor UNIFESP Google Scholar
Pereira Gomes, Jose Alvaro Autor UNIFESP Google Scholar
Hofling-Lima, Ana Luisa Autor UNIFESP Google Scholar
Abstract PURPOSE: To evaluate the efficacy of the Esclera scleral contact lens (SCL) treatment and its impact on clinical testing for moderate to severe dry eye disease (DED). DESIGN: Prospective interventional case series. METHODS: A total of 41 eyes from 25 patients with moderate to severe DED were evaluated for the Esclera SCL treatment. Best-corrected visual acuity (BCVA), tear osmolarity, the Schirmer I test, tear film breakup time (TBUT), corneal and conjunctival staining, meibo-mian grading, and Ocular Surface Disease Index and SF-36v2 questionnaires were assessed before and after the SCL treatment. These values were compared to assess the real benefit of using SCL as a treatment for DED. RESULTS: Forty-one eyes from 25 patients were fitted with SCL for management of DED. The underlying diseases were Stevens-Johnson syndrome (22 eyes), Sjogren syndrome (11 eyes), graft-vs-host disease (2 eyes), dry eye after keratomileusis in situ (2 eyes), and undifferentiated ocular surface disease (4 eyes). BCVA improved from 0.703 +/- 0.55 logMAR with habitual correction to 0.406 +/- 0.43 logMAR with SCL (P<.001). There was a significant decrease in tear osmolarity values (338.1 +/- 27.1 to 314.25 +/- 38.8 mOsm/L, P<.001) and van Bijsterveld scores (3.63 +/- 2.33 to 2.63 +/- 2.46 grade, P=.015) between the baseline and 12 months after SCL wear. There were also significant improvements in dry eye symptoms and quality of life as assessed by the OSDI and SF-36v2 questionnaires (both with P<.001). CONCLUSIONS: The Esclera SCL treatment had a positive impact on tear osmolarity and van Bijsterveld score, as well as an improvement in the patients' BCVA, dry eye symptoms, and quality of life. (C) 2016 by Elsevier Inc. All rights reserved.
xmlui.dri2xhtml.METS-1.0.item-coverage New York
Language English
Sponsor BRAZILIAN GOVERNMENT COORDENACAO DE APERFEICOAMENTO DE PESSOAL DE Nivel Superior-CAPES Foundation (Brasilia, DF, Brazil)
Mediphacos Inc. (Belo Horizonte, MG, Brazil)
Date 2016
Published in American Journal Of Ophthalmology. New York, v. 163, p. 167-173, 2016.
ISSN 0002-9394 (Sherpa/Romeo, impact factor)
Publisher Elsevier Science Inc
Extent 167-173
Origin http://dx.doi.org/10.1016/j.ajo.2015.11.034
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000371447500022
URI https://repositorio.unifesp.br/handle/11600/57907

Show full item record




File

Name: WOS000371447500022.pdf
Size: 430.7Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account